Treatment of cancer using GFR α-4 chimeric antigen receptor
US10851149B2 · kind B2 · utility
2Cited by
10References
32Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Aug 14, 2015 |
| Grant date | Dec 1, 2020 |
| Priority date | — |
| Expiry date | Aug 14, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/70
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to compositions and methods for treating diseases, disorders or conditions associated with the expression of the Glycosyl-phosphatidylinositol (GPI)-linked GDNF family α-receptor 4 (GFRα4).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.